Coronavirus Covid-19 Testing: Symptoms, Asymptomatic, and Serology for Immunity
Report Code: KNJ265141 No. of Pages: 98 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
WinterGreen Research announces that it has a new study: Covid-19 - The Way Forward: Testing . Germany was able to decrease it death rate from covid-19 with extensive, early and continuous testing. The US is faced with waves of covid-19 illnesses that all too frequently result in death. Testing provides a way forward, the study documents the tests available and likely scenarios.
LEXINGTON, Massachusetts (April 3, 2020) – WinterGreen Research announces that it has a new study available that describes United States testing for the rapidly evolving COVID-19 pandemic. Testing capability forecasts for PCR assay and Molecular Diagnostics are presented in two week increments for the next 6 months. Availability of Serological testing is also forecast for detection of the virus after recovery. All major vendors are included and can be compared with quantities, qualities, and test time.
Covid-19 Testing 2020: The Way Forward describes the timelines the virus is likely to take regarding quarantines and successive waves of infection. Successive waves of infection are expected to strike the US population after the shelter in place restrictions start to be lifted. Intensive testing is needed at every stage of covid-19 disease management. The testing scenarios and the vendors with good test kits are described in detail.
Successive waves of infection are expected to continue to at least January 2021. One thing that will stop them is if effective vaccine is found. The 2020 study has 96 pages, 12 tables and figures. The tables describe in enormous detail what testing kits are available and the significance of further testing. It describes testing capacity and length of time to administer testing. It describes the impact of testing and the need for serological testing as the quarantines begin to end.
PCR testing – as used by the CDC and WHO initially – is very labor intensive, and has several points along the path of doing a single test where errors may occur – which may lead to headline issues of a false positive, the test showing evidence of the virus when it’s not actually there, or a false negative, suggesting someone doesn’t have the virus when in fact they do.
The virus and the resulting disease, Covid-19, have hit Germany with force: According to Johns Hopkins University, the country had more than 91,000 laboratory-confirmed infections by Saturday morning, more than any other country except the United States, Italy and Spain. But with 1,275 deaths, Germany’s fatality rate stood at 1.3 percent, compared with 12 percent in Italy, around 10 percent in Spain, France and Britain, 4 percent in China and 2.5 percent in the United States. Even South Korea, a model of flattening the curve, has a higher fatality rate, 1.7 percent.
When the first cases of COVID-19 were reported in the US, two labs at the CDC were the only ones permitted to conduct COVID-19 testing, using a test developed by the agency’s own researchers. When the CDC tried to expand testing by providing its test kits to state and local public health labs, there were problems with the initial version of the kits, The CDC, despite initially faulty reagents making its first test kits unreliable, is now offering accurate RT-PCR Diagnostic Panels and positive and human specimen controls.
“Had {the US} done more testing from the very beginning and caught cases earlier,” said Dr. Nuzzo, of Johns Hopkins, “we would be in a far different place.”
Companies Profiled (Market Leaders)-
Abbott Labs Leverages ID Now Platform w/ Installed Base of 15,000
Abbott Labs M2000
Thermo Fisher Scientific
CDC
bioMérieux
Danaher / Cepheid
Danaher / IDT
LabCorp
Quest Diagnostics
Roche SunSure Biotech
OPKO / BioReference Laboratories
Hologic
Mammoth
Other - 260 Companies
Key Topics for Coronavirus Covid-19 Testing
Coronavirus
Covid-19
SARS Testing
Patient Testing 2020
Symptoms Testing
Asymptomatic Testing
Serology for Testing Immunity
We support various market segment programs; provides trusted technical services to the marketing departments. It carries out accurate market share and forecast analysis services for a range of commercial and government customers’ globally. These are all vital market research support solutions requiring trust and integrity. Coronavirus Covid-19 Patient Testing 2020 Executive Summary The study is designed to give a comprehensive overview of the Covid-19 - The Way Forward: Testing market segment. Research represents a selection from the mountains of data available of the most relevant and cogent market materials, with selections made by the most senior analysts. Commentary on every aspect of the market from independent analysts creates an independent perspective in the evaluation of the market. In this manner the study presents a comprehensive overview of what is going on in this market, assisting managers with designing market strategies likely to succeed. Table of Contents: Abstract: Covid-19 Testing Patients with Symptoms, Patients with No Symptoms and Serology Testing for Immunity and Quarantine Avoidance TABLE OF CONTENTS COVID-19 TESTING IN THE US: EXECUTIVE SUMMARY 10 Testing and Covid-19 PCR Testing for Covid-19 Serological Testing for Covid-19 1. US COVID-19 TESTING – CDC AND VENDOR ABILITY TO PROVIDE TESTS 1.1 Covid-19 PCR Testing Market Driving Forces 1.2 Covid-19 Testing 1.3 Covid-19 Testing Equipment Missed the Mark 1.3.1 Covid-19 Need for Quarantine 1.3.2 Viral Load 1.3.3 Covid-19 Testing on Patients with Symptoms 1.3.4 Covid-19 Serological Contact Testing 1.3.5 Covid-19 Serological Testing on Social Contacts of Patients with Symptoms 1.4 Covid-19 Testing Prices 2. DELAYS IN US COVID-19 TESTING AND INTERNATIONAL RESPONSE 2.1 Broader Testing Delayed 2.2 Government and Open Market Control of Testing 2.3 Extracting Virus from Blood Sample 3. COVID-19 TESTING REGIONAL ANALYSIS 3.1 Covid-19 Number People Affected Worldwide 3.2 US 3.3 China 3.4 India 3.5 Europe 3.6 Asia 3.7 Rest of World 4. COVID-19 MOLECULAR DIAGNOSTICS TESTING TECHNOLOGY 4.1 Coronavirus Assay Testing Technique Polymerase Chain Reaction (PCR) 4.2 Panther Fusion Automates The Complex Steps Involved In Molecular Diagnostics Covid-19 Testing 4.2.1 Molecular Diagnostics 4.3 Scientists Need The Actual Virus In Order To Check A Diagnostic Test 5. COVID-19 TESTING EQUIPMENT COMPANY PROFILES 5.1 Abbott Laboratories 5.2 Alphabet Verify 5.3 Astrotech 5.4 Beckman Coulter 5.5 Bill Gates 5.6 bioMérieux 5.7 Bodysphere 5.8 Center for Disease Control and Prevention CDC 5.8.1 CDC Serology Test for SARS-CoV-2 5.9 Co-Diagnostics, Inc. 5.10 Danaher 5.10.1 Cepheid is part of Danaher (NYSE:DHR). 5.10.2 Cepheid 5.10.3 Danaher / Integrated DNA Technologies (IDT) 5.11 US FDA 5.12 GenMark Diagnostics 5.13 Hologic 5.14 Hong Kong University of Science and Technology (HKUST) 5.15 LabCorp 5.15.1 LabCorp Testing 5.16 Logix Smart 5.17 Mammoth Biosciences 5.18 Opko / BioReference Laboratories 5.18.1 OPKO Health 5.19 Quidel 5.20 Quest Diagnostics 5.20.1 Quest / Roche Partnership 5.20.2 Roche IVD test / Quest Diagnostics LDT 5.21 Roche Diagnostics 5.21.1 Roche IVD Test for COVID-19 Offered by Quest Diagnostics 5.22 Sherlock Biosciences 5.23 SunSure Biotech 5.24 Tianjin University China 5.25 Thermo Fisher Scientific 5.25.1 Thermo Fisher Scientific / Applied Biosystems 5.25.2 Thermo Fisher / Dutch Diagnostics Firm Qiagen 5.26 Tianjin University of China. 5.27 Where to Look for More Covid-19 Information 6. COVID-19 PCR TESTING: DESCRIPTION AND DYNAMICS 6.1 Rapidly Evolving COVID-19 6.2 COVID-19 a Respiratory Illness 6.2.1 Covid-19 Symptoms 6.2.2 Diagnostic Testing for COVID-19 6.2.3 Guidance for Testing 6.2.4 Covid-19 Quarantine 6.3 PCR and Molecular Diagnostic Testing Status 6.4 Where to get Tested 6.5 Testing: False Negative and False Positive 6.6 Serology Testing for COVID-19 List of Figures Abstract: Covid-19 Testing Patients with Symptoms, Patients with No Symptoms and Serology Testing for Immunity and Quarantine Avoidance Figure 1. US Covid-19 Serological Testing to see if a Person Has Already Had the Corona Virus and Does Not Need to Be Put in Quarantine, April 1 2020 to September 1, 2020 Capability Forecasts by Two Week Intervals Figure 2. US Serological Testing on People Who Have Been in Contact with Covid-19 Patients with Symptoms, May 1 to October 1, 2020 Figure 3. Covid-19 US Testing Market Driving Forces Figure 4. Covid-19 Testing for Quarantine Implementation Figure 5. CDC and Vendor implementation of Covid-19 Testing Figure 6. Testing in the Next Phase of COVID-19 Outbreak: Suppression Figure 7. Covid-19 Characteristics Impacted by Testing Figure 8. Testing Characteristics Impacting Covid-19 Healthcare Management Figure 9. Covid-19 Testing Initially Quarantined Population Management Timelines Figure 10. Covid-19 Testing Second Wave Quarantined Population Management Timelines Figure 11. Impact on Testing of Waves of Critically Ill Patients with Covid-19 Figure 12. US Covid-19 Testing Equipment Market Share Description, Number of Tests Day, Tests per Week Capability, Time to Administer, April 1, 2020 Figure 13. US Covid-19 Testing Equipment Company Description, Number of Tests per Day, Tests per Week Capability, April 1, 2020, Time to Administer, April 1, 2020 Figure 14. US Covid-19 Patient with Symptom Testing Capability April 1 2020 to September 1, 2020 Forecasts by Two Week Intervals, Testing Patients Who Present Symptoms at Care Facility or Hospital Figure 15. US Serological Testing on People Who Have Been in Contact with Covid-19 Patients with Symptoms, May 1 to October 1, 2020 Figure 16. Abbott Virus Detection Machine Figure 17. GenMark Diagnostics Coronavirus ePlex Testing System Figure 18. Hologic’s Panther Fusion® SARS-CoV-2 test Figure 19. Quest Healthcare Provider Fact Sheet Figure 20. Governor Cuomo - The Face of COVID-19 Resistance
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com